Tokyo, Japan

Yoshinori Kosugi

USPTO Granted Patents = 3 


Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • Setagaya-ku, JP (2014)
  • Tokyo, JP (2010 - 2015)

Company Filing History:


Years Active: 2010-2015

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yoshinori Kosugi: Innovator in Cancer Research

Introduction

Yoshinori Kosugi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of 3 patents, his work focuses on the development of cancer markers and evaluation methods.

Latest Patents

Kosugi's latest patents include a novel cancer marker and a method for evaluating cancer using this marker. The invention provides a means to assess the onset, preclinical stage, clinical stage, or prognosis of cancer in a subject. The cancer marker comprises at least one miRNA selected from hsa-miR-92 and hsa-miR-494, specifically for cancers excluding breast cancer. The evaluation method involves detecting the expression level of this cancer marker in a biological sample collected from a subject.

Career Highlights

Throughout his career, Yoshinori Kosugi has worked with notable organizations such as NEC Corporation and Tokyo Medical University. His experience in these institutions has contributed to his expertise in cancer research and innovation.

Collaborations

Kosugi has collaborated with esteemed colleagues, including Masahiko Kuroda and Kosuke Oikawa. These partnerships have further enhanced his research and development efforts in the field of cancer evaluation.

Conclusion

Yoshinori Kosugi's contributions to cancer research through his innovative patents highlight his dedication to improving cancer evaluation methods. His work continues to impact the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…